CLP 257

• CAT Number: I010692
• CAS Number: 1181081-71-9
• Molecular Formula: C14H14FN3O2S
• Molecular Weight: 307.35
• Purity: ≥95%
• Synonyms: (5Z)-5-[(4-Fluoro-2-hydroxyphenyl)methylene]-2-(tetrahydro-1-(2H)-pyridazinyl)-4(5H)-thiazolone
• Target: Potassium Channel
• Solubility: Soluble to 100 mM in DMSO
• Storage: Store at 4℃
• IUPAC Name: (5Z)-2-(diazinan-1-yl)-5-[(4-fluoro-2-hydroxyphenyl)methylidene]-1,3-thiazol-4-one
• InChI: InChI=1S/C14H14FN3O2S/c15-10-4-3-9(11(19)8-10)7-12-13(20)17-14(21-12)18-6-2-1-5-16-18/h3-4,7-8,16,19H,1-2,5-6H2/b12-7-
• InChIKey: SKCADXVKQRCWTR-GHXNOFRVSA-N
• SMILES: C1CCN(NC1)C2=NC(=O)C(=CC3=C(C=C(C=C3)F)O)S2

CLP 257 (Cat.No:I010692) is a potent and selective agonist of the G protein-coupled receptor 119 (GPR119). GPR119 activation has been shown to enhance glucose-dependent insulin secretion and improve glucose control. CLP 257 has demonstrated promising effects in preclinical studies for the treatment of type 2 diabetes mellitus. It is being investigated as a potential therapeutic agent to regulate glucose metabolism and insulin secretion. Clinical trials are underway to evaluate its efficacy and safety in humans.